Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rimonabant for overweight or obesity.

C Curioni1, C André

  • 1Universidade do Estado do Rio de Janeiro, Instituto de Medicina Social, Rio de Janeiro, Brazil. c_curioni@uol.com.br

The Cochrane Database of Systematic Reviews
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The influence of rainfall events on the toxicity of urban wastewaters to freshwater mussels Elliptio complanata.

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP·2024
Same author

After-Results of Treatment of Caries by Geranium-Formol.

International dental journal (Philadelphia, Pa.)·2023
Same author

Comparative toxicity of urban wastewater and rainfall overflow in caged freshwater mussel <i>Elliptio complanata</i>.

Frontiers in physiology·2023
Same author

Evidence of polystyrene nanoplastic contamination and potential impacts in Mya arenaria clams in the Saint-Lawrence estuary (Canada).

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP·2023
Same author

Alf Brodal's stroke in 1972: A brilliant self-report by a neuroanatomy professor.

Revue neurologique·2022
Same author

Physicochemical and microbiological stability of insulin eye drops in an artificial tear vehicle used in the treatment of refractory neurotrophic keratopathy.

Journal francais d'ophtalmologie·2022
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Rimonabant (a cannabinoid-1 receptor antagonist) at 20 mg resulted in modest weight loss of approximately 5% in overweight and obese adults. However, this dose also led to significantly more adverse effects, particularly neurological and gastrointestinal issues.

Area of Science:

  • Pharmacology
  • Obesity Research
  • Clinical Trials

Background:

  • Rising global obesity rates necessitate effective weight management strategies.
  • Rimonabant, a cannabinoid-1 receptor antagonist, has been explored for weight reduction.
  • Phase III trials are evaluating rimonabant for long-term efficacy and safety in obese individuals.

Purpose of the Study:

  • To assess the efficacy and safety of rimonabant for weight loss in overweight and obese adults.
  • To compare the effects of different rimonabant dosages against placebo.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches (MEDLINE, EMBASE, Cochrane Library, LILACS).
  • Inclusion criteria: RCTs comparing rimonabant with placebo or other weight loss interventions in adults.

Related Experiment Videos

  • Primary outcomes: weight loss, morbidity, and adverse events; data collected and analyzed by two independent reviewers.

    • Main Results:

    • Rimonabant 20 mg yielded a 4.9 kg greater weight reduction compared to placebo after one year, alongside improvements in waist circumference and lipid profiles.
    • Rimonabant 5 mg showed a less significant weight reduction (1.3 kg greater than placebo) with no notable effects on lipids or blood pressure.
    • The 20 mg dose was associated with significantly more adverse events (nervous system, psychiatric, gastrointestinal); attrition rates were high (~40%).

    Conclusions:

    • Rimonabant 20 mg offers modest weight loss (approx. 5%) but carries a higher risk of adverse effects.
    • Potential benefits of even modest weight loss should be weighed against safety concerns.
    • Further high-quality, longer-term studies are required to establish definitive recommendations for rimonabant in obesity management.